Table 5 Participants with 30% or more than 30% recovery in VAS, WOMAC, and Lequesne, 2 and 6 months follow up
|  | Outcome | PRP + HA Number (%) | PRP Number (%) | HA Number (%) | P- value |
|---|---|---|---|---|---|
2 months follow up | WOMAC Total | 26 (83.9) | 26 (81.3) | 24 (82.8) | 0.963 |
VAS | 30 (96.8) | 30 (93.8) | 29 (100) | 0.390 | |
Lequesne Total | 11(35.5) | 10 (31.3) | 13 (44.8) | 0.563 | |
6 months follow up | WOMAC Total | 23 (74.2) | 23 (71.9) | 19 (65.5) | 0.749 |
VAS | 29 (93.5) | 28 (87.5) | 25 (86.2) | 0.616 | |
Lequesne Total | 19 (61.3) | 13 (40.6) | 6 (20.7) | 0.006 | |
VAS [P-value] | WOMAC [P-value] | Lequesne Total [P-value] | |||
PRP + HA vs. PRP [0.672] | PRP + HA vs. PRP [>  0.999] | PRP + HA vs. PRP [0.133] | |||
PRP + HA vs. HA [0.417] | PRP + HA vs. HA [0.576] | PRP + HA vs. HA [0.002] | |||
PRP vs. HA [>  0.999] |  |  | |||